News
BDXA
0.0000
0.00%
0.00
CONMED names John Gallagher CFO, effective July 15, 2026
PUBT · 6h ago
BD EVP and President Michael David Garrison sells 1,100 shares for $166,628
PUBT · 6d ago
BD CEO Thomas E. Polen Jr disposes of 20,209 shares worth $2.96 million
PUBT · 06/03 16:45
BD files Form 3 disclosing EVP and BDI President Peter Menziuso as beneficial owner
PUBT · 06/02 18:05
MHRA: RECALLED BATCHES INCLUDES CHLORAPREP 2% 1ML APPLICATORS AND CHLORAPREP FREPP 2% 1.5 ML APPLICATORS
Reuters · 06/02 13:14
MHRA: BECTON DICKINSON UK RECALLS BATCHES OF CHLORAPREP APPLICATOR DUE TO POTENTIAL BREACH OF STERILITY IN PACKAGING PROCESS
Reuters · 06/02 13:14
BECTON DICKINSON & CO - NO PATIENT SAFETY SIGNALS REPORTED FOR CHLORAPREP - SEC FILING
Reuters · 05/29 12:40
BD resumes U.S. ChloraPrep shipments after FDA warning letter prompts added release testing
PUBT · 05/29 12:40
BD EVP, Chief Revenue Officer Michael Feld disposes of 75 common shares worth $11,051.25
PUBT · 05/27 17:42
China's commerce ministry holds meeting with foreign pharmaceutical firms
Reuters · 05/22 13:21
BD unit issues €600 million 3.855% notes due 2033, BD guarantees offering
PUBT · 05/20 21:05
BUZZ-U.S. STOCKS ON THE MOVE-T1 Energy, Home Depot, X-Energy
Reuters · 05/19 15:48
Avantor names Gerard Porreca executive vice president, quality and regulatory
PUBT · 05/19 10:05
BD names Peter Menziuso EVP, president of BD Interventional
PUBT · 05/18 10:50
PETER MENZIUSO NAMED EVP AND PRESIDENT, BD INTERVENTIONAL
Reuters · 05/18 10:50
BD unit Becton Finance prices €600 million 3.855% notes due 2033
PUBT · 05/12 20:32
BECTON DICKINSON EURO FINANCE S.À R.L: FILES FOR EURO-DENOMINATED 600 MLN 3.855% NOTES OFFERING DUE 2033 - SEC FILING
Reuters · 05/11 20:39
BECTON DICKINSON EURO FINANCE SA RL - TO OFFER EURO-DENOMINATED NOTES WITH ANNUAL CASH INTEREST PAYMENTS - SEC FILING
Reuters · 05/11 10:05
BECTON DICKINSON <BDX.N>: BARCLAYS RAISES TARGET PRICE TO $204 FROM $202
Reuters · 05/11 10:00
U.S. RESEARCH ROUNDUP-Airbnb, HII, Tesla
Reuters · 05/11 07:27
More
Webull provides a variety of real-time BDXA stock news. You can receive the latest news about BECTON DICKINSON through multiple platforms. This information may help you make smarter investment decisions.
About BDXA
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.